Daily Stock Analysis, CMRX, Chimerix Inc, priceseries

Chimerix Inc. Daily Stock Analysis
Stock Information
Open
5.44
Close
5.37
High
5.64
Low
5.23
Previous Close
5.44
Daily Price Gain
-0.07
YTD High
6.05
YTD High Date
Feb 16, 2017
YTD Low
4.33
YTD Low Date
Jan 3, 2017
YTD Price Change
0.83
YTD Gain
18.28%
52 Week High
6.47
52 Week High Date
Apr 19, 2016
52 Week Low
3.50
52 Week Low Date
Jun 27, 2016
52 Week Price Change
0.34
52 Week Gain
6.76%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 11. 2015
38.52
Feb 26. 2015
41.24
10 Trading Days
7.05%
Link
LONG
May 8. 2015
36.46
Jun 1. 2015
41.52
15 Trading Days
13.88%
Link
LONG
Jul 10. 2015
46.90
Aug 6. 2015
52.35
19 Trading Days
11.62%
Link
LONG
Oct 26. 2015
35.92
Nov 6. 2015
38.79
9 Trading Days
7.98%
Link
LONG
Apr 13. 2016
5.67
Apr 26. 2016
6.04
9 Trading Days
6.47%
Link
LONG
Sep 12. 2016
4.82
Sep 29. 2016
5.62
13 Trading Days
16.65%
Link
LONG
Nov 8. 2016
4.10
Nov 28. 2016
5.03
13 Trading Days
22.74%
Link
Company Information
Stock Symbol
CMRX
Exchange
NasdaqGM
Company URL
http://www.chimerix.com
Company Phone
919.806.1074
CEO
M. Michelle Berrey
Headquarters
North Carolina
Business Address
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC 27713
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001117480
About

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the United States.

Description

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the United States. The company's lead product candidate is brincidofovir (CMX001), a nucleotide analog, which is in Phase III clinical trials for the prevention of cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant (HCT) recipients and in kidney transplant recipients, as well as to treat adenovirus infection in allogeneic HCT patients. It is also developing CMX157, a nucleotide analog that is in Phase II clinical stage for the treatment of HIV and hepatitis B virus infection. The company's preclinical testing product comprises CMX669, a compound with in vitro activity for the treatment of BK virus and CMV. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.